It is well-known that aminoglycoside antibiotics can cause significant hearing loss and
vestibular deficits that have been described in animal studies and in clinical reports. The …

Current evidence supports the favourable safety profile of vancomycin in neonates. Further
studies that address safety concerns relating to high-dose intermittent dosing regimens are …

Background Understanding the risk factors for hearing loss is essential for designing the
Belgian newborn hearing screening programme. Accordingly, they needed to be updated in …

Objectives Wide variations in antibiotic use in very preterm infants have been reported
across centres despite similar rates of infection. We describe 10 year trends in use of …

Objective To evaluate the impact of gentamicin exposure on sensorineural hearing loss
(SNHL) in very low birth weight (VLBW) infants. Methods Exposure to gentamicin was …

Objective: The objective of this study was to examine the impact of Coagulase-negative
staphylococcus (CoNS) sepsis in preterm infants on the neurodevelopmental outcomes at …

Background Vancomycin is an extensively used anti-infective drug in neonatal ICUs.
However, exposure–toxicity relationships have not been clearly defined. Objectives To …

Background: Coagulase-negative Staphylococcus (CoNS) is the most common cause of
bloodstream infections (BSI) in hospitalized infants. CoNS BSI is most reliably treated with …

Background Despite differences in types of infection and causative organisms,
pharmacokinetic-pharmacodynamic (PKPD) targets of vancomycin therapy derived from …

Purpose: The aim of this work is to identify the most significant risk factors for hearing
impairment in high risk neonates hospitalized at our Neonatal Intensive Care Unit (NICU) …